Inhibition by eicosapentaenoic acid of oxidized-LDL- and lysophosphatidylcholine-induced human coronary artery smooth muscle cell production of endothelin

J Vasc Res. 2001 Jul-Aug;38(4):379-88. doi: 10.1159/000051069.

Abstract

The objectives of the present study were (1) to determine whether oxidized low-density lipoprotein (LDL) and lysophosphatidylcholine (lyso-PC), a major phospholipid component of oxidized LDL, stimulate the production of endothelin-1 (ET)-1 in cultured human coronary artery smooth muscle cells (SMCs), and (2) to examine the possible effect of an antiatherogenic agent, eicosapentaenoic acid (EPA), on oxidized-LDL- and lyso-PC-stimulated ET-1 production in these cells. Oxidized LDL (10-50 microg/ml) and lyso-PC (10(-7) to 10(-5) mol/l) stimulated ET-1 production in a concentration-dependent manner. By contrast, the effects of native LDL and phosphatidylcholine were modest or absent. Lyso-PC (10(-7) to 10(-5) mol/l) and oxidized LDL (10-50 microg/ml) significantly induced particulate protein kinase C (PKC) activation. Lyso-PC- and oxidized-LDL-stimulated ET-1 production was significantly inhibited by PKC inhibitor, PKC (19-36). EPA (80-160 micromol/l) clearly suppressed ET-1 production stimulated by oxidized LDL and lyso-PC in a concentration-dependent manner. Furthermore, EPA (160 micromol/l) significantly inhibited lyso-PC (10(-5) mol/l)- and oxidized LDL (50 microg/ml)-induced particulate PKC activation. Results suggest that oxidized LDL and lyso-PC stimulate ET-1 production by a mechanism involving activation of PKC, and that EPA suppresses ET-1 production stimulated by lyso-PC as well as oxidized LDL probably through the modulation of PKC in human coronary artery SMCs. EPA may exert an antiatherosclerotic effect, in part, through these mechanisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology
  • Cells, Cultured
  • Coronary Vessels / drug effects*
  • Coronary Vessels / metabolism
  • Dose-Response Relationship, Drug
  • Eicosapentaenoic Acid / pharmacology*
  • Endothelin-1 / biosynthesis*
  • Enzyme Activation / drug effects
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Lipoproteins, LDL / pharmacology*
  • Lysophosphatidylcholines / pharmacology*
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / metabolism
  • Peptide Fragments / pharmacology
  • Phosphatidylcholines / pharmacology
  • Platelet-Derived Growth Factor / pharmacology
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism
  • Protein Kinase C / pharmacology
  • Tetradecanoylphorbol Acetate / pharmacology

Substances

  • Endothelin-1
  • Enzyme Inhibitors
  • Lipoproteins, LDL
  • Lysophosphatidylcholines
  • Peptide Fragments
  • Phosphatidylcholines
  • Platelet-Derived Growth Factor
  • oxidized low density lipoprotein
  • protein kinase C (19-36)
  • Angiotensin II
  • Eicosapentaenoic Acid
  • Protein Kinase C
  • Tetradecanoylphorbol Acetate